Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Acting Mesalamine in Post-Infective IBS
NCT01412372Phase 3Completed
- Sponsor
- University of Utah
- Start
- Jun 2010
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in irritable bowel syndrome (IBS) comparing Mesalamine Arm with Placebo Arm (2 arms). Primary endpoint: Change in Average Overall Bowel Symptom Score at 8 weeks. Started Jun 2010; status: completed.
02
Drugs
Salcrozine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT01412372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412372.